News

A new analysis of OCT biomarkers may help elucidate the utility of OCT biomarkers as therapeutic predictors of ranibizumab treatment among eyes with diabetic macular edema.

New data expands upon the growing perception that allergenic food introduction early in a child’s life may lessen the possibility of allergy developments.

Juliana Reed, MS, believes that there should be legislative incentives and preferred status for lower cost biosimilars in all government programs, with robust competition and accountability for PBMs not to limit access.

An analysis of 3 nationally representative data sets found that SDOH across domains of economic stability, educational attainment, health care access and quality, neighborhood and built environment, and social context were significant predictors of poor vision.

Insomnia shows associations with higher rates of outpatient visits, hospitalizations, and fills for medications, longer hospital length of stay, and higher hospitalization costs.

Juliana Reed, MS, believes that there needs to be action that addresses the anti-competitive behaviors of pharmacy benefit managers (PBMs) and provides access to all biosimilars.

The Gold Standard Pathway Study noted statistically significant reductions in mean IOP and mean medication count from baseline was observed in both treatment arms at all visits.

Results show ISR is a promising behavioral treatment for insomnia, which can reduce sleep latency, increase total sleep time as well as sleep efficiency, and may serve as an alternative to traditional treatments.

April 7, 2023 marks the 75th anniversary of the WHO’s definition of health—a concept that experts point out is yet to be achieved, and faces many modern hurdles.

A retrospective, propensity score-matched analysis details significant risk reductions achieved with bariatric surgery in patients with nonalcoholic fatty liver disease and obesity.

New data from a study in China suggests that practicing tai chi may benefit cognitive function in adults dealing with diabetes as well as cognitive impairment issues.

The March 2023 rheumatology month in review highlights recent data regarding nipocalimab as a treatment option for hemolytic disease of the fetus and newborn and myasthenia gravis, hyperbaric oxygen therapy for fibromyalgia, and the differences among specialties in biosimilar uptake.

The evolving recognition of inflammation as a driver of cardiovaacular risk and has led some to speculate around a potential role for colchicine 0.5 mg, which has a PDUFA date in June 2023, for reducing risk in patients with ASCVD.

A novel allergen and immunotherapy adherence and persistence checklist was developed to allow for more insight into adherence and to open this information to prescribing clinicians.

Patients with no prior colonoscopy had significantly higher all-cause mortality and colorectal cancer specific mortality compared to patients with detected colorectal cancer.

The cross-sectional analysis found a significant association between greater insomnia severity and worsened quality of life, decreased productivity, and increased healthcare resource utilization.

A new study has found individuals with depression and insomnia show significantly less activity in the prefrontal cortex during verbal fluency tests, suggesting that sleep quality is an important indicator in fNIRS screening.

The ESSENCE-2 study reported superiority of the water-free cyclosporine ophthalmic solution to vehicle in tCFS score at day 29, confirming results from ESSENCE-1.

Announced on April 6, the recall, which is the most serious of its kind, includes all Readers used with the FreeStyle Libre, FreeStyle Libre 14 day, and FreeStyle Libre 2 Flash Glucose Monitoring Systems distributed from November 2017-February 2023, which totals more than 4 million devices in the US.

The Biosimilars Forum is concerned with the limited access to lower-cost biosimilars, specifically regarding the 8 adalimumab biosimilars set to launch in July, due to pharmacy benefits managers controlling access to 80% of the US market.

The FDA’s move to withdraw hydroxyprogesterone caproate injection (Makena) was a joint decision by both the FDA’s Commissioner and its Chief Scientist.

After a two-year intensive therapy period, visual acuity was maintained or improved in nearly half of the ranibizumab-treated group and more than half of the aflibercept-treated group, but severely declined during the post-intensive period.

New research on a patient with recalcitrant eosinophilic annular erythema who had been successfully treated with benralizumab suggests a therapeutic possibility for EAE patients.

The risk of minor nuisances, violating APS law, and violating criminal law were higher in the nonadherence group.

An analysis of data from patients in the DELIVER and DAPA-HF trials in the Americas provides an overview of the benefits of dapagliflozin in Black patients relative to White patients.

New data shows that there are several major reasons for the perceptions of patients with hidradenitis suppurativa viewing their own access to healthcare as problematic.

Increased age, male sex, COPD, CHF, dependent functional status, and C. difficile infection were associated with increased mortality within 30 days of surgery.

An analysis of more than 2 dozens studies provides and overview of the evolving safety profile of balloon pulmonary angioplasty in the treatment of chronic thromboembolic pulmonary hypertension in a period lasting from 2013-2022.

Our highlights from March 2023 included a teaser episode of a new KOL-led podcast, a feature elucidating a rare eye disease, and a look at the development of new therapies for geographic atrophy.

New data quantify the exposure to wildfire particulate matter among schoolchildren in California, finding that interventions in a small number of schools may reduce the overall burden of wildfire PM2.5 exposure.